Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))

Bojana Milojkovic Kerklaan; Veronique Diéras; Christophe Le Tourneau; Marja Mergui-Roelvink; Alwin D.R. Huitema; Hilde Rosing; Jos H. Beijnen; Sandrine Marreaud; Anne Sophie Govaerts; Martine J. Piccart-Gebhart; Jan H.M. Schellens; Ahmad Awada

doi:10.1007/s00280-012-2064-y

Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))

Bojana Milojkovic Kerklaan, Veronique Diéras, Christophe Le Tourneau, Marja Mergui-Roelvink, Alwin D.R. Huitema, Hilde Rosing, Jos H. Beijnen, Sandrine Marreaud, Anne Sophie Govaerts, Martine J. Piccart-Gebhart, Jan H.M. Schellens, Ahmad Awada^*

^*Corresponding author for this work

Clinical Pharmacy

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Number of pages	1
Journal	Cancer Chemotherapy and Pharmacology
Volume	71
Issue number	2
DOIs	https://doi.org/10.1007/s00280-012-2064-y
Publication status	Published - 1 Feb 2013

Access to Document

10.1007/s00280-012-2064-y

Cite this

Milojkovic Kerklaan, B., Diéras, V., Le Tourneau, C., Mergui-Roelvink, M., Huitema, A. D. R., Rosing, H., Beijnen, J. H., Marreaud, S., Govaerts, A. S., Piccart-Gebhart, M. J., Schellens, J. H. M., & Awada, A. (2013). Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62)). Cancer Chemotherapy and Pharmacology, 71(2). https://doi.org/10.1007/s00280-012-2064-y

@article{dc362fae634a4421b778333a48de33c3,

title = "Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))",

author = "{Milojkovic Kerklaan}, Bojana and Veronique Di{\'e}ras and {Le Tourneau}, Christophe and Marja Mergui-Roelvink and Huitema, {Alwin D.R.} and Hilde Rosing and Beijnen, {Jos H.} and Sandrine Marreaud and Govaerts, {Anne Sophie} and Piccart-Gebhart, {Martine J.} and Schellens, {Jan H.M.} and Ahmad Awada",

year = "2013",

month = feb,

day = "1",

doi = "10.1007/s00280-012-2064-y",

language = "English",

volume = "71",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer-Verlag",

number = "2",

}

Milojkovic Kerklaan, B, Diéras, V, Le Tourneau, C, Mergui-Roelvink, M, Huitema, ADR, Rosing, H, Beijnen, JH, Marreaud, S, Govaerts, AS, Piccart-Gebhart, MJ, Schellens, JHM & Awada, A 2013, 'Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))', Cancer Chemotherapy and Pharmacology, vol. 71, no. 2. https://doi.org/10.1007/s00280-012-2064-y

Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62)). / Milojkovic Kerklaan, Bojana; Diéras, Veronique; Le Tourneau, Christophe et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 71, No. 2, 01.02.2013.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Erratum

T2 - Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))

AU - Milojkovic Kerklaan, Bojana

AU - Diéras, Veronique

AU - Le Tourneau, Christophe

AU - Mergui-Roelvink, Marja

AU - Huitema, Alwin D.R.

AU - Rosing, Hilde

AU - Beijnen, Jos H.

AU - Marreaud, Sandrine

AU - Govaerts, Anne Sophie

AU - Piccart-Gebhart, Martine J.

AU - Schellens, Jan H.M.

AU - Awada, Ahmad

PY - 2013/2/1

Y1 - 2013/2/1

UR - http://www.scopus.com/inward/record.url?scp=84874106537&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-2064-y

DO - 10.1007/s00280-012-2064-y

M3 - Comment/Letter to the editor

AN - SCOPUS:84874106537

SN - 0344-5704

VL - 71

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

Milojkovic Kerklaan B, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema ADR, Rosing H et al. Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62)). Cancer Chemotherapy and Pharmacology. 2013 Feb 1;71(2). doi: 10.1007/s00280-012-2064-y

Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62))

Access to Document

Other files and links

Cite this